Understanding The Optimal Dosing Strategy For Regorafenib In Mcrc
Let's dive into the details surrounding The Optimal Dosing Strategy For Regorafenib In Mcrc. Tanios Bekaii-Saab, MD, FACP, discusses
Key Takeaways about The Optimal Dosing Strategy For Regorafenib In Mcrc
- Cathy Eng, MD, addresses
- Alan Venook, MD, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center discusses ...
- Tanios Bekaii-Saab, MD, FACP, provides an overview of the ReDOS trial, which compared safety and efficacy with a ...
- The panelists, John L. Marshall, MD; Tanios Bekaii-Saab, MD; Johanna Bendell, MD; Richard Kim, MD; and Charles S. Fuchs, MD ...
- Dr. Heinz-Josef Lenz discusses use and
Detailed Analysis of The Optimal Dosing Strategy For Regorafenib In Mcrc
In this episode, Kanwal Raghav, MD, and Rachel Riechelmann, MD, PhD, discuss key data supporting contemporary Panelists John Marshall, MD; Alan P. Venook, MD; Johanna Bendell, MD; and Tanios Bekaii-Saab, MD, describe their clinical ... Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses a randomized phase II trial to evaluate
Panelists John L. Marshall, MD; Cathy Eng, MD; Daniel G. Haller, MD; Tara E. Seery, MD; and Tanios-Bekaii Saab, MD; outline ...
That wraps up our extensive overview of The Optimal Dosing Strategy For Regorafenib In Mcrc.